BRPI0412380A - compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos - Google Patents

compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos

Info

Publication number
BRPI0412380A
BRPI0412380A BRPI0412380-8A BRPI0412380A BRPI0412380A BR PI0412380 A BRPI0412380 A BR PI0412380A BR PI0412380 A BRPI0412380 A BR PI0412380A BR PI0412380 A BRPI0412380 A BR PI0412380A
Authority
BR
Brazil
Prior art keywords
compounds
disease
pharmaceutical compositions
compositions containing
type
Prior art date
Application number
BRPI0412380-8A
Other languages
English (en)
Inventor
Thalaththani Ralalag Vedananda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0412380A publication Critical patent/BRPI0412380A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE BENZENOSSULFONILAMINO E COMPOSIçõES FARMACêUTICAS QUE CONTêM ESSES COMPOSTOS". A presente invenção refere-se a compostos de fórmula (I) que proporcionam agentes farmacológicos que se ligam a Receptores Ativados por Proliferadores de Peroxissoma (PPARs). Conseqüentemente, os compostos da presente invenção são úteis para o tratamento de condições mediadas pela atividade de receptor PPAR em mamíferos. Essas condições incluem dislipidemia, hiperlipidemia, hipercolesteremia, aterosclerose, hipertrigliceridemia, insuficiência cardíaca, infarto do miocárdio, doenças vasculares, doenças cardiovasculares, hipertensão, obesidade, inflamação, artrite, câncer, doença de Alzheimer, distúrbios da pele, doenças respiratórias, distúrbios oftálmicos, doenças inflamatórias intestinais (IBDs), colite ulcerativa e doença de Crohn, e condições em que tolerância a glicose prejudicada, hiperglicemia e resistência à insulina estão implicadas, tais como diabetes tipo 1 e tipo 2, e Síndrome X.
BRPI0412380-8A 2003-07-08 2004-07-07 compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos BRPI0412380A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48587003P 2003-07-08 2003-07-08
PCT/EP2004/007442 WO2005005421A1 (en) 2003-07-08 2004-07-07 Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds

Publications (1)

Publication Number Publication Date
BRPI0412380A true BRPI0412380A (pt) 2006-09-19

Family

ID=34062103

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412380-8A BRPI0412380A (pt) 2003-07-08 2004-07-07 compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos

Country Status (9)

Country Link
US (1) US7538135B2 (pt)
EP (1) EP1646628A1 (pt)
JP (1) JP2009513523A (pt)
CN (1) CN100447139C (pt)
AU (1) AU2004255342C1 (pt)
BR (1) BRPI0412380A (pt)
CA (1) CA2531418A1 (pt)
MX (1) MXPA06000118A (pt)
WO (1) WO2005005421A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
EP1648422A4 (en) * 2003-07-28 2007-09-19 Reddys Lab Inc Dr TREATMENT AND PREVENTION OF CARDIOVASCULAR ACCIDENTS
EP1893583B1 (en) 2005-05-31 2012-04-04 Pfizer Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
EP1937658A1 (en) 2005-10-06 2008-07-02 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
WO2007039175A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
ATE513829T1 (de) * 2005-10-06 2011-07-15 Sanofi Aventis Bicyclische arylsulfonsäureä1,3,4ü-thiadiazol-2- yl-amide, verfahren zu ihrer herstellung und ihre verwendung als pharmazeutika
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
EP2054056A4 (en) * 2006-08-16 2010-08-25 J David Gladstone Inst A Testa SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE
DK2054397T3 (en) 2006-08-16 2016-01-18 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone SMALL MOLECULAR INHIBITORS OF KYNURENIN-3-MONOOXYGENASE
JP4891111B2 (ja) * 2007-02-16 2012-03-07 富士フイルム株式会社 ズームレンズ
EP1995241B1 (en) 2007-03-23 2010-03-17 ICAgen, Inc. Inhibitors of ion channels
EP2240474B1 (en) 2007-12-26 2012-03-14 Sanofi Cyclic pyridyl-n-(1,3,4)-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
WO2009129267A2 (en) 2008-04-14 2009-10-22 The Board Of Regents Of The University Of Texas System Small molecule inhibitors of the pleckstrin homology domain and methods for using same
IL266563B (en) 2009-10-06 2022-09-01 Millennium Pharm Inc Heterocyclic compounds useful as pdk1 inhibitors
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
CN101774922B (zh) * 2010-01-29 2012-12-26 浙江大学 2,3-二羟基苯甲酸酯类化合物及制备和应用
EP3318872A1 (en) 2011-07-20 2018-05-09 The Regents of the University of California Dual-pore device
WO2013043744A2 (en) 2011-09-21 2013-03-28 Inception 1, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL2839232T3 (pl) 2012-04-16 2020-04-30 Pyrotek Inc. Urządzanie do zanurzania stapianego złomu metalowcgo
CA2895162C (en) 2012-12-14 2021-03-09 D. Lynn Kirkpatrick Methods and compositions for inhibiting cnksr1
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20200013086A (ko) 2014-12-11 2020-02-05 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
GB2533136A (en) * 2014-12-11 2016-06-15 Antabio Sas Compounds
CA2983260C (en) 2015-04-20 2024-01-23 Phusis Therapeutics, Inc. Sulfonamide compounds, compositions and methods for inhibiting cnksr1
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
HRP20250505T1 (hr) 2016-05-20 2025-06-20 Xenon Pharmaceuticals Inc. Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3281937A1 (en) * 2016-08-09 2018-02-14 Dompé farmaceutici S.p.A. Sulfonamides as gpr40- and gpr120-agonists
ES2967410T3 (es) 2016-12-09 2024-04-30 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos
ES2946917T3 (es) 2017-07-21 2023-07-27 Antabio Sas Compuestos químicos
CN112262142B (zh) 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
MX2021001380A (es) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4253126B2 (ja) * 1998-01-29 2009-04-08 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ調節剤
AU2852100A (en) 1999-01-19 2000-08-29 Tularik Inc. Methods of modulating uric acid levels
YU72201A (sh) * 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
US6298255B1 (en) * 1999-06-09 2001-10-02 Aspect Medical Systems, Inc. Smart electrophysiological sensor system with automatic authentication and validation and an interface for a smart electrophysiological sensor system
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
MXPA01013199A (es) 1999-06-30 2003-08-20 Tularik Inc Compuestos para la modulacion de la actividad de ppary.
AU6118001A (en) * 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
EP1357908A4 (en) * 2001-01-30 2009-07-15 Merck & Co Inc "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS"
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CN100447139C (zh) 2008-12-31
CA2531418A1 (en) 2005-01-20
US7538135B2 (en) 2009-05-26
JP2009513523A (ja) 2009-04-02
WO2005005421A1 (en) 2005-01-20
AU2004255342B2 (en) 2008-11-20
AU2004255342A1 (en) 2005-01-20
CN1816546A (zh) 2006-08-09
US20070043020A1 (en) 2007-02-22
MXPA06000118A (es) 2006-04-27
AU2004255342C1 (en) 2009-05-14
EP1646628A1 (en) 2006-04-19

Similar Documents

Publication Publication Date Title
BRPI0412380A (pt) compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos
BRPI0410779A (pt) heterociclos de n-acil nitrogênio como ligantes de receptores ativados por proliferador de peroxissoma
BR0214305A (pt) Compostos heterocìclicos e métodos de uso
BRPI0414536A (pt) compostos orgánicos
CO2021008089A2 (es) Agonistas de glp-1r y usos de los mismos
AR123156A1 (es) Agonistas de glp-1r y sus usos
ZA202205346B (en) Glp-1 receptor agonist and use thereof
BRPI0518425A2 (pt) composiÇço farmacÊutica compreendendo Ácidos graxos âmega-3 e agonista e/ou antagonista ppar e composiÇço farmacÊutica em forma de dose unitÁria compreendendo fenofibrato e sistema solvente
BR112021020335A2 (pt) Agonistas glp-1r e usos dos mesmos
CY1121423T1 (el) Φαρμακευτικη συνθεση για την αντιμετωπιση ενος μεταβολικου συνδρομου
EA200970342A1 (ru) Антагонисты рецептора глюкагона, композиции, содержащие такие соединения, и способы применения
CL2008002351A1 (es) Compuestos derivados de 6-triazolopiridazina-sulfanil benzotiazol y bencimidazol; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del cancer.
PE20050249A1 (es) Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos
ECSP088120A (es) Derivados de piridazinona como agonistas del receptorde la hormona tiroidea
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
BRPI0717156B8 (pt) inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende
CL2007003874A1 (es) Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
BRPI1013645A2 (pt) conjugado de fármaco anticorpo e sua composição farmacêutica
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
EP2401263A4 (en) SUBSTITUTED AZOL DERIVATIVES, PHARMACEUTICAL COMPOSITION WITH THE DERIVATIVES AND METHOD FOR THE TREATMENT OF MORBUS PARKINSON THEREWITH
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
MX2019008317A (es) Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.
BR0313377A (pt) Bifenilcarnboxamidas substituìdas por n-aril piperidina como inibidores de secreção de apolipoproteìna b
MX2023011377A (es) Derivados de ciclobutilo 1,3-sustituidos y sus usos.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.